DRUG TRANSPORT IN THE LIVER - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 400

161. Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. 2001. Bilateral pharmacokinetic
interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am
J Transplant 1(4):382-386.
162. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler
M, Mangold B, Christians U. 1997. Accumulation of lovastatin, but not pravastatin,
in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin
Pharmacol Ther 62(3):311-321.
163. Martin J, Krum H. 2003. Cytochrome P450 drug interactions within the HMG-CoA
reductase inhibitor class: Are they clinically relevant? Drug Saf 26(1):13-21.
164. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass
AS, Schneck DW. 2004. Rosuvastatin pharmacokinetics in heart transplant recipients
administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther
76(2):167-177.
165. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E. 2003.
Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male
volunteers. Clin Ther 25(11):2822-2835.
166. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. 2005.
Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol
Ther 78(4):388-399.
167. Treiber A, Schneiter R, Delahaye S, Clozel M. 2004. Inhibition of organic anion
transporting polypeptide-mediated hepatic uptake is the major determinant in the
pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol
Exp Ther 308(3):1121-1129.
168. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum
M, Kivisto KT, Neuvonen PJ. 2005. Polymorphic organic anion transporting polypeptide
1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther
77(6):468-478.
169. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. 2002. Gemfibrozil greatly
increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72(6):685-

691.
170. Shitara Y, Hirano M, Sato H, Sugiyama Y. 2004. Gemfibrozil and its glucuronide inhibit
the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated
hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the
mechanism of the clinically relevant drug-drug interaction between cerivastatin and
gemfibrozil. J Pharmacol Exp Ther 311(1):228-236.
171. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. 2000. Plasma concen-
trations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther
68(2):122-129.
172. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. 2001.
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil
but not by bezafibrate. Clin Pharmacol Ther 69(5):340-345.
173. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. 2003. Gemfibrozil increases
plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin

Pharmacol Ther 73(6):538-544.
174. Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M, Demartis
A, Laufer R, Hochman JH, Prueksaritanont T, Lin JH. 2005. Effects of fibrates on